Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

businesswire.com
GDRX GoodRx is expanding its offerings to include access to Ozempic® pill pricing, enhancing its role as a consumer access platform for pharmaceutical manufacturers and potentially increasing user engagement and revenue.

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients SANTA MONICA, Calif.--( BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk’s Ozempic® pill (oral semaglutide), helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide.

“As Novo Nordisk brings the Ozempic pill to market, we’re focused on helping patients access it with clear, transparent pricing,” said Wendy Barnes, President & CEO of GoodRx. “The availability of an oral formulation under the Ozempic brand marks an important step forward, offering a convenient alternative to the established injectable. It also reflects GoodRx’s expanding work with Novo Nordisk across the entire semaglutide portfolio and its role in supporting patient access.”

“We’re excited to bring the Ozempic pill to the GoodRx platform – adding a newly approved oral option under a brand people know and trust, and giving healthcare professionals more flexibility to tailor treatment for each patient,” said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. “Working with GoodRx helps expand access to our medicines, now including the Ozempic pill, with a clear self-pay pricing model.”

More broadly, this announcement demonstrates how GoodRx is evolving beyond a pricing solution into a broader consumer access platform for pharmaceutical manufacturers, helping them reach patients directly, convert clinically appropriate demand, and deliver transparent pricing seamlessly at the pharmacy counter.

*The Ozempic pill is now available to eligible self-pay patients at a cash price of $149 per month for the 1.5mg dose, $199 per month for the 4mg dose, and $299 per month for the 9mg dose.

About GoodRx

GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $100 billion on the cost of their medications.

​GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

GoodRx Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings, convenience and accessibility; the expected benefits and value of our offerings to consumers, GoodRx, Novo Nordisk, and other pharmaceutical manufacturers; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.